Patients with colorectal cancer were among the first to receive targeted therapies. These drugs aim to block the cancer-causing proteins that trigger out-of-control cell growth while sparing healthy tissues. But some patients are not eligible for these treatments because they have cancer-promoting mutations that are believed to cause resistance to these drugs. Now, physician-scientists have used computer modeling and cell studies to discover that more patients may be helped by a common class of targeted therapies than previously thought.
